Anti-tumour necrosis factor (anti-TNF) agents used in inflammatory bowel disease (IBD) are also indicated in some patients with psoriasis. 1 However, 222 cases of anti-TNFinduced psoriasis in IBD patients have been reported to date which sets up a paradoxical side effect of this pharmacological class. [2] [3] [4] We performed a retrospective analysis of IBD patients attending our clinics that developed psoriasis during treatment with anti-TNF. We have analysed the following features: 1) type of IBD; 2) concomitant treatment with other immunosuppressive agents; 3) type of anti-TNF; 4) period from anti-TNF institution until development of psoriasis; 5) location of skin lesions; and 6) type of dermatological treatment instituted.
Of the 132 IBD patients treated with anti-TNF between 2002 and 2012 (infliximab 88, adalimumab 44), eleven patients developed psoriasis and were therefore included in the study. Eight (73%) were female. Mean age at the time of the study was 38 years. 1) Type of IBD: Crohn's disease (CD) n = 10, ulcerative colitis (UC) n = 1; 2) At the time of psoriasis development, only one patient was being treated with combination of anti-TNF with azathioprine; 3) Anti-TNF involved: infliximab n = 9, adalimumab n = 2; 4) Mean time from starting of anti-TNF until development of psoriasis: 11.8 months (range 2-32 months); 5) Location of skin lesions (some patients with involvement of multiple body parts): scalp 82%, palmoplantar 55%, extensor surfaces36%, trunk 18%, ears 18%, face 8% (Fig. 1) . 6) All patients were treated with topical betamethasone plus calcipotriol. Response to therapy: complete 27%, partial 46%, no response 27%. In 5 patients anti-TNF treatment was withdrawn due to psoriasis, which led to an amelioration of skin lesions in all of them.
In our study the overall incidence of anti-TNF induced psoriasis in patients with IBD was 8.3%. This paradoxical reaction can occur several years after starting of anti-TNF agents, and may be severe enough to require cessation of such therapy. 3, 4 In this series 91% of patients were treated with anti-TNF alone at the time of psoriasis development, and in 55% of them, it was possible to continue the anti-TNF agent while controlling the skin disease with topical agents. E-mail address: paulosalgueiro@gmail.com (P. Salgueiro).
